Based on these research results, the University of Michigan Comprehensive Cancer Center will soon begin a new clinical study of a drug similar to rapamycin in adult patients with chronic myeloid leukemia, or CML. The study will be led by Moshe Talpaz, M.D., the UMCCCs director of translational research.
Link to this comment:
All Comments (0)